Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Clover Biopharmaceutical

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates

              Contact the Supplier

              Lead Product(s): Adjuvanted COVID-19 S-Trimer vaccine,AS03,CpG-1018

              Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019

              Highest Development Status: Phase II/ Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: GlaxoSmithKline

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 04, 2020

              Details:

              Clover’s protein-based COVID-19 vaccine candidates adjuvanted with either GSK’s pandemic adjuvant system or Dynavax’s CpG 1018 plus alum induced strong neutralizing immune responses in 150 adult and elderly subjects from the Phase 1 clinical study.

              Fosun Pharmaceutical

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              China's Fosun to End BioNTech's COVID-19 Vaccine Trial, Seek Approval for Another

              Contact the Supplier

              Lead Product(s): BNT162

              Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162

              Highest Development Status: Phase II/ Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: BioNTech SE

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 04, 2020

              Details:

              Fosun will focus instead on seeking Chinese approval for BioNTech’s other experimental vaccine which is in final-stage human trials in the United States, Fosun’s Chief Medical Officer Hui Aimin told Reuters in an interview.

              Sinopharm

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              Shanghai Fosun Pharma, Sinopharm Group Sign Deal to Supply BioNTech Coronavirus Vaccine Candidate

              Contact the Supplier

              Lead Product(s): BNT162

              Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162

              Highest Development Status: Phase II/ Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: Fosun Pharmaceutical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement September 07, 2020

              Details:

              Shanghai Fosun Pharmaceutical has signed a strategic cooperation agreement with Sinopharm Group to supply a coronavirus vaccine candidate developed by German firm BioNTech.

              PharmaCompass__DigitalAd